ZOM - Zomedica Pharmaceuticals Corp.

NYSE American - NYSE American Delayed Price. Currency in USD
0.3382
-0.0097 (-2.78%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.3479
Open0.3400
Bid0.3417 x 29200
Ask0.3488 x 3100
Day's Range0.3350 - 0.3496
52 Week Range0.2000 - 1.8500
Volume21,314
Avg. Volume134,823
Market Cap39.633M
Beta (3Y Monthly)0.16
PE Ratio (TTM)N/A
EPS (TTM)-0.2440
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.00
Trade prices are not sourced from all markets
  • Newsfile

    CORRECTION FROM SOURCE: Zomedica Pushes TRUFORMA(TM) Closer To Commercialization, Targeting $2.7 Billion Companion Animal Diagnostics Market

    Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (TSXV: ZOM) - In the article headline published on October 1, 2019, the reference to Zomedica's TRUFORMA companion pet diagnostic device was incorrectly titled as TRUFORM. This error was made by a third-party responsible for syndication processes and should not reflect on Zomedica, its trademarks, or its pipeline properties. A copy of the entire release follows.Miami Beach, Florida--(Newsfile Corp. - October 3, 2019) - Zomedica Pharmaceuticals Corp. ...

  • Newsfile

    Zomedica Pushes TRUFORMA (TM) Closer To Commercialization, Targeting $2.7 Billion Companion Animal Diagnostics Market

    Miami Beach, Florida--(Newsfile Corp. - October 1, 2019) - Zomedica, Inc. (NYSE American: ZOM) (TSXV: ZOM) is getting closer to commercializing its first potentially industry-changing product, TRUFORMA™, a point of care diagnostic platform with initial assays used to diagnose thyroid and adrenal disorders in dogs and cats. The device, which is on pace to launch by the end of first quarter of 2020, is expecting to earn a large share of the ...

  • GlobeNewswire

    Zomedica names Dr. Stephanie Morley President

    Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (ZOM.V), a veterinary diagnostic and pharmaceutical company, today announced that Dr. Stephanie Morley, Chief Operations Officer and VP of Product Development, has been promoted to the role of President of Zomedica. Dr. Morley, who joined the initial management team of Zomedica shortly after its founding, has over 15 years of experience as a life science executive and practicing veterinarian with a broad career in operations, business development and clinical veterinary practice.

  • PCG Research Announces Publication of Report Covering Zomedica Pharmaceuticals Corp.
    Newsfile

    PCG Research Announces Publication of Report Covering Zomedica Pharmaceuticals Corp.

    Developer of Diagnostic and Pharmaceutical Solutions for the Companion Animal Market with Commercialization Activities Approaching New York, New York--(Newsfile Corp. - September 11, 2019) - PCG Research, the equity research division of PCG Advisory, Inc., a leading investor relations and strategic advisory firm based in New York City and focused on small and micro-cap public companies, today announced it has initiated coverage on Zomedica Pharmaceuticals, Corp. (NYSE: ZOM) PCG Research, the equity research division of ...

  • ACCESSWIRE

    Zomedica to Present at the Fall Investor Summit on Monday, September 16 in New York City

    NEW YORK, NY / ACCESSWIRE / September 11, 2019 / Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (TSX-V:ZOM), a veterinary diagnostic and pharmaceutical company, today announced its Chief Financial ...

  • GlobeNewswire

    Zomedica to Present at RHK Capital 2019 Disruptive Growth Conference, Fall Investor Summit, and Sidoti & Company Fall 2019 Investor Conference

    ANN ARBOR, Mich., Sept. 03, 2019 -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (TSX-V: ZOM), a veterinary diagnostic and pharmaceutical company, today announced that.

  • GlobeNewswire

    Animal Health Veteran Johnny D. Powers Joins Zomedica Board of Directors

    Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (ZOM.V) (“Zomedica” or the “Company”), a veterinary diagnostic and pharmaceutical company, today announced that, subject to the approval of the TSX Venture Exchange, Johnny D. Powers has been appointed to Zomedica’s board of directors as an independent director. Additionally, Powers will also serve as a member of the audit, compensation, and corporate governance committees of the board of directors. Powers has more than 30 years of experience leading business strategy, operations, sales and marketing, and product development in the human and pet medical diagnostics markets.

  • ACCESSWIRE

    Zomedica Inc. Prepares to Launch Veterinarian Diagnostic Device, TRUFORMA(TM); Has Potential to Change Diagnostic Landscape in Animal Health (NYSE American: ZOM)

    TRUFORMA™ is the company's innovative diagnostic tool that aims to replace old-fashioned methods of diagnosis that require patient samples to be sent to an outside lab for testing before therapeutic or prescription treatments can be offered. Now, with modern innovations coming to market by companies like Zomedica, a fast, accurate point-of-care diagnosis can be provided right at the clinic. In doing so, Zomedica can help to streamline the vet care industry.

  • GlobeNewswire

    Zomedica Announces Second Quarter 2019 Financial Results

    Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (ZOM.V) (“Zomedica” or “Company”), a veterinary diagnostic and pharmaceutical company, today reported consolidated financial results for the second quarter ended June 30, 2019. “We have made significant progress in the first half of 2019 with our development of TRUFORMA™, Zomedica’s point-of-care biosensor platform, as well as our digital data platform and other product lines,” said Gerald Solensky Jr., Chairman and CEO of Zomedica. $5,000,000 of the purchase price was paid in May 2019 and $7,000,000 was paid in June 2019.  The preferred shares do not have voting rights except to the extent required by applicable law and are not convertible into the Company’s common shares.

  • GlobeNewswire

    Zomedica Announces TRUFORMA™ Assay Updates and R&D Expansion

    Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (ZOM.V), a veterinary diagnostic and pharmaceutical company, today announced additional development progress on two assays for its TRUFORMA™ point-of-care biosensor platform. Development of what Zomedica believes is the first-ever point-of-care assay for canine endogenous adrenocorticotropic hormone (eACTH) and an assay for feline thyroid stimulating hormone (feline TSH) demonstrates the potential of TRUFORMA™.

  • GlobeNewswire

    Zomedica’s Dr. Bonnie Bragdon to Speak at AVMA Convention 2019 on Sunday, August 4

    ANN ARBOR, Mich., July 25, 2019 -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (TSX-V: ZOM), a veterinary diagnostic and pharmaceutical company, today announced Dr..

  • GlobeNewswire

    Zomedica Announces Initiation of a Digital Data Platform Enhancing its Diagnostic Pipeline

    Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (ZOM.V), a veterinary diagnostic and pharmaceutical company, announced it has initiated the development of a digital customer data platform to enhance customer experience and its diagnostic pipeline. Development efforts are focused on providing veterinarians access to diagnostic test result data and insights into patterns of disease across animal populations.

  • Zacks Small Cap Research

    ZOM: One Instrument; Multiple Solutions

    The high level of ownership stimulates the $19 billion2 in estimated veterinary care spending and the mid-single digit growth rate that the industry is experiencing. As pets become a more important part of the family, the quality of their health care is also receiving more attention. There is a parallel between improvements in therapies and diagnostics for human and animal health.

  • GlobeNewswire

    Zomedica Announces Completion of Initial Development of a Lymphoma Assay for its Canine Cancer Liquid Biopsy Platform

    Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (ZOM.V), a veterinary diagnostic and pharmaceutical company, today announced that it has completed initial development work on a blood-borne lymphoma cancer assay intended for use with its canine cancer liquid biopsy platform. According to the American Veterinary Medical Association, one in four dogs will develop cancer during their lifetime. Lymphomas represent approximately 10-25% of all cancers diagnosed in dogs.

  • GlobeNewswire

    Zomedica to Present at Raymond James Life Sciences and MedTech Conference

    ANN ARBOR, Mich., June 12, 2019 -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (TSX-V: ZOM), a veterinary diagnostic and pharmaceutical company, today announced that it.

  • GlobeNewswire

    Zomedica Announces $7 Million Second Tranche Closing of Preferred Shares

    ANN ARBOR, Mich., June 10, 2019 -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (TSX-V: ZOM) (“Zomedica” or “Company”), a veterinary diagnostic and pharmaceutical.

  • GlobeNewswire

    Zomedica Announces Achievement of Product Development Milestones on its TRUFORMA™ Point-of-Care Diagnostic Platform

    Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (ZOM.V), a veterinary diagnostic and pharmaceutical company, today announced that TRUFORMA™, its point-of-care biosensor platform, recently achieved two important product development milestones. The milestones achieved are beta finalization of the instrument design and the completion of feasibility testing of the TRUFORMA™ platform’s first assays. The standard of care for total T4, fT4, TSH, and cortisol is reference lab immunoassays generally run on expensive laboratory equipment.

  • GlobeNewswire

    Zomedica Announces First Quarter 2019 Financial Results

    Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (ZOM.V) (“Zomedica” or “Company”), a veterinary diagnostic and pharmaceutical company, today reported consolidated financial results for the first quarter ended March 31, 2019. “During the quarter, we continued to advance the development of our unique product pipeline of novel diagnostics and innovative therapeutics,” said Gerald Solensky Jr., Chairman and CEO of Zomedica. In January 2019, Zomedica announced the achievement of the product development milestone for ZM-017, our canine cancer liquid biopsy diagnostic platform, by Celsee, Inc. Celsee elected to receive its milestone payment in equity resulting in the issuance to Celsee of an aggregate of 657,894 common shares at an ascribed price of $1.52 (C$2.00).

  • GlobeNewswire

    Zomedica Announces Private Placement of Preferred Shares

    Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (ZOM.V) (“Zomedica” or “Company”), a veterinary diagnostic and pharmaceutical company, today announced that it has entered into subscription agreements to sell $12,000,000 of its newly created Series 1 Preferred Shares to an accredited investor under a private placement at a purchase price of $1,000,000 per Series 1 Preferred Share. $5,000,000 of the purchase price was paid on May 9, 2019 and 5 Series 1 Preferred Shares have been issued to the subscriber. The remaining $7,000,000 is expected to be paid on or prior to June 7, 2019, at which time a further 7 Series 1 Preferred Shares will be issuable to the subscriber.

  • GlobeNewswire

    Zomedica Pharmaceuticals Corp. Announces Pricing of $3 Million Underwritten Public Offering of Common Shares

    Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (ZOM.V) (“Zomedica” or the “Company”), a veterinary diagnostic and pharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 6,521,740 common shares, at a price to the public of $0.46 per share.  The Company expects to receive gross proceeds of approximately $3 million from the offering.  The offering is expected to close on or about March 28, 2019, subject to customary closing conditions. H.C. Wainwright & Co. is acting as sole book-running manager for the offering.

  • GlobeNewswire

    Zomedica Pharmaceuticals Corp. Announces Proposed Public Offering of Common Shares

    Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (ZOM.V) (“Zomedica” or the “Company”), a veterinary diagnostic and pharmaceutical company, today announced it has commenced an underwritten public offering of its common shares. The Company intends to grant the underwriters of the offering a 30-day option to purchase up to an additional 15 percent of the number of common shares sold in connection with the offering. The Company intends to use the net proceeds from the offering for the continued development of its diagnostic platform and therapeutic candidates, including making milestone payments, as they come due, under the Company’s existing license and collaboration agreements, and other general corporate and working capital purposes.

  • GlobeNewswire

    Zomedica Initiates ZM-006 Pilot Efficacy Study and Provides Corporate Updates

    Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (ZOM.V), a veterinary diagnostic and pharmaceutical company, initiated enrollment in its pilot efficacy study at the University of Georgia College of Veterinary Medicine to evaluate ZM-006, a transdermal methimazole formulation for the treatment of chronic hyperthyroidism in cats. The ZM-006 pilot efficacy study is being conducted to evaluate Zomedica’s transdermal methimazole formulation and, assuming positive study results, provide data for a future FDA Center for Veterinary Medicine (FDA-CVM) approved pivotal trial.

  • GlobeNewswire

    Zomedica Pharmaceuticals Corp. Announces Year End 2018 Financial Results

    Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (ZOM.V) (“Zomedica” or “Company”), a veterinary diagnostic and pharmaceutical company, today reported consolidated financial results for the year ended December 31, 2018.

  • GlobeNewswire

    Zomedica Appoints Dr. Bonnie Bragdon as Vice President of Veterinary Affairs

    Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (ZOM.V), a veterinary diagnostic and pharmaceutical company, today announced the appointment of Bonnie Bragdon, DVM, MS, as Vice President of Veterinary Affairs. In this new company position, she will lead the veterinary medical strategy as it relates to industry trends, strategic partnerships, marketing, education and training to support Zomedica’s commercial product strategy, reporting to Chief Commercial Officer Bruk Herbst. “I am pleased to welcome Dr. Bragdon to the Zomedica Team.

  • GlobeNewswire

    Zomedica Announces $4.28 Million Private Placement Closing and Corporate Update

    Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (ZOM.V) (“Zomedica” or “Company”), a veterinary diagnostic and pharmaceutical company, today announced the completion of its previously announced private placement offering, pursuant to which it has issued an aggregate of 2,815,789 common shares at a price of $1.52 (C$2.00) per share, for aggregate gross proceeds of $4,280,000 (approximately C$5,649,600), in the United States to accredited investors only pursuant to the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506(b) of Regulation D thereunder. Zomedica intends to use the net proceeds of the offering to fund its cash expenditure obligations under the Company’s exclusive development and supply agreement with Qorvo Biotechnologies, LLC (Qorvo), a wholly-owned subsidiary of Qorvo, Inc. (QRVO).